Compare Anheuser-Busch Inbev SA (BUD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs State Street SPDR S&P Biotech ETF — how do they compare? Anheuser-Busch Inbev SA trades at $79.28 (market cap $159.01B), while State Street SPDR S&P Biotech ETF trades at $158.93. The key difference: Anheuser-Busch Inbev SA pays a 1.67% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Anheuser-Busch Inbev SA nearer its low. Which is the better fit depends on your goals.
| BUD | XBI | |
|---|---|---|
Market Cap | $159.01B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $86.48 | $164.28 |
52-Week Low | $57.93 | $86.92 |
Enterprise Value | $223.42B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.3, down 4.56% on the day, with a bearish technical signal from moving averages and oscillators. Fundamentally, the company reported Q2 2026 EPS of $1.21, beating estimates, and maintains strong cash flow with $14.88B from operations in 2025. Revenue for 2025 was $59.32B, with net income margin improving to 11.52%. Recent news includes mixed institutional activity and Q2 earnings coverage highlighting volume growth and premium brand strength.
The outlook is supported by analyst consensus with a $90.17 price target and 57.78% buy ratings, but risks include recent shareholder share sales and competitive pressures. Earnings growth and deleveraging trends provide upside, while technical weakness near support at $79 requires monitoring for stability.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
